Contineum Therapeutics Inc Class A Common Stock CTNM
News
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis